Karl Vivot is a researcher at Inserm since October 2023, with previous postdoctoral experience at IGBMC from November 2016 to October 2023, where research focused on lysosomal insulin granule degradation in Type 2 Diabetes, and at CRCHUM from November 2012 to October 2016, investigating the role of RGS16 in promoting insulin secretion and β-cell proliferation. Additionally, Karl Vivot completed a PhD at Université de Strasbourg from 2009 to 2012, concentrating on cellular and molecular mechanisms of pancreatic islet loss during transplantation, and earlier research as a Master’s degree student involved the impact of rapamycin on pancreatic islet inflammation.
This person is not in the org chart
This person is not in any teams
This person is not in any offices